Method of assaying apolipoprotein ai for the in vitro diagnosis of colorectal cancer

Abstract

The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Apolipoprotein AI tumor marker in a biological sample taken from a patient suspected of having colorectal cancer, it being understood that the assay is not turbidimetric. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

1 - 4 . (canceled) 
     
     
         5 . A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Apolipoprotein AI marker in a biological sample taken from a patient suspected of having colorectal cancer, the sample being remote from the tumor, wherein the assay is not a turbidimetric assay. 
     
     
         6 . The method of  claim 5 , wherein the biological sample is a biological fluid. 
     
     
         7 . The method of  claim 5 , wherein the marker is a protein and the presence thereof is determined by a biochemical test or by mass spectrometry. 
     
     
         8 . The method of  claim 5 , further comprising determining the presence of at least one other tumor marker selected from the group consisting of Leukocyte Elastase Inhibitor, Ezrin, Aminoacylase 1, Liver Fatty Acid-Binding Protein, Intestinal Fatty Acid-Binding Protein, Apolipoprotein AII, and I-Plastin. 
     
     
         9 . The method of  claim 5 , further comprising determining the presence of at least one other tumor marker selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, Galectin-3, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Keratin type II Cytoskeletal 8, Keratin type I Cytoskeletal 18, Keratin type I Cytoskeletal 19, Epithelial-Cadherin, CEA, Villin, CA19-9, CA 242, CA 50, CA 72-2, Testosterone, TIMP-1, Cripto-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, the detection of methylated DNA in the blood, the detection of specific alterations in fecal DNA fragments, and the detection of fecal human hemoglobin. 
     
     
         10 . The method of  claim 5 , further comprising determining the presence of at least one other tumor marker selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, Galectin-3, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Epithelial-Cadherin, CEA, CA19-9, Testosterone, TIMP-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, and the detection of fecal human hemoglobin. 
     
     
         11 . The method of  claim 5 , further comprising determining the presence of Galectin-3 marker. 
     
     
         12 . The method of  claim 5 , further comprising determining the presence of Apolipoprotein AII, E-Cadherin, and Galectin-3 markers. 
     
     
         13 . The method of  claim 5 , further comprising determining the presence of Apolipoprotein AII, Testosterone, Leukocyte Elastase Inhibitor, LDH-B, L-FABP, E-Cadherin, and Galectin-3 markers. 
     
     
         14 . A process comprising the use of Apolipoprotein AI for early diagnosis, screening, therapeutic follow-up, prognosis, and relapse diagnosis in relation to colorectal cancer, wherein the process does not comprise a turbidimetric assay. 
     
     
         15 . The process of  claim 14 , further comprising the use of at least one other tumor marker chosen from the following markers: Leukocyte Elastase Inhibitor, Ezrin, Aminoacylase 1, Liver Fatty Acid-Binding Protein, Intestinal Fatty Acid-Binding Protein, Apolipoprotein AII, and I-Plastin. 
     
     
         16 . The process of  claim 14 , further comprising the use of at least one other tumor marker selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, Galectin-3, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Keratin type II Cytoskeletal 8, Keratin type I Cytoskeletal 18, Keratin type I Cytoskeletal 19, Epithelial-Cadherin, CEA, Villin, CA19-9, CA 242, CA 50, CA 72-2, Testosterone, TIMP-1, Cripto-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, the detection of methylated DNA in the blood, the detection of specific alterations in fecal DNA fragments, and the detection of fecal human hemoglobin. 
     
     
         17 . The process of 14, further comprising the use of at least one other tumor marker selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, Galectin-3, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Epithelial-Cadherin, CEA, CA19-9, Testosterone, TIMP-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, and the detection of fecal human hemoglobin. 
     
     
         18 . The process of  claim 14 , further comprising the use of Galectin-3 marker. 
     
     
         19 . The process of  claim 14 , further comprising the use of Apolipoprotein AII, E-Cadherin, and Galectin-3 markers. 
     
     
         20 . The process of  claim 14 , further comprising the use of Apolipoprotein AII, Testosterone, Leukocyte Elastase Inhibitor, LDH-B, L-FABP, E-Cadherin, and Galectin-3 markers.